title: Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials.
abstract: Twin studies document substantial heritability for successful abstinence from smoking. A genome-wide association study has identified markers whose allele frequencies differ with nominal P<0.005 in nicotine-dependent clinical trial participants who were successful vs unsuccessful in abstaining from smoking; many of these results are also supported by data from two additional samples. More study is required to precisely determine the variance in quitting success that can be accounted for by the single-nucleotide polymorphisms that are currently identified and to precisely classify individuals who may display varying degrees of genetic vs environmental effects into quitters or nonquitters. However, the data at hand do allow us to model the effects of genotypic stratification in smoking cessation trials. We identify relationships between the costs of identifying and genotyping prospective trial participants vs the costs of performing the clinical trials. We quantitate the increasing savings that result from genetically stratified designs as recruiting/genotyping costs go down and trial costs increase. This model helps to define the circumstances in which genetically stratified designs may enhance power and reduce costs for smoking cessation clinical trials.
authors.affiliation: Molecular Neurobiology Branch, NIH-IRP, NIDA, Baltimore, MD 21224, USA. guhl@intra.nida.nih.gov
authors.forename: G R
authors.initials: GR
authors.lastname: Uhl
authors.forename: T
authors.initials: T
authors.lastname: Drgon
authors.forename: C
authors.initials: C
authors.lastname: Johnson
authors.forename: J E
authors.initials: JE
authors.lastname: Rose
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics; D003198:Computer Simulation; D017046:Cost Savings; D005820:Genetic Testing / Q000191:economics; D005838:Genotype; D006801:Humans; D018803:Models, Economic; D008957:Models, Genetic; D018579:Patient Selection; D010641:Phenotype; D012907:Smoking / Q000235:genetics*; D016540:Smoking Cessation; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome
references.citation: Arch Gen Psychiatry. 2008 Jun;65(6):683-93
references.pmid: 18519826
references.citation: Arch Gen Psychiatry. 1998 Nov;55(11):967-72
references.pmid: 9819064
references.citation: Addiction. 1997 Apr;92(4):469-72
references.pmid: 9177068
references.citation: N Engl J Med. 1991 Aug 1;325(5):311-5
references.pmid: 2057036
references.citation: Psychopharmacology (Berl). 1998 Jun;137(4):345-50
references.pmid: 9676894
references.citation: Psychol Med. 2007 Sep;37(9):1357-67
references.pmid: 17466111
references.citation: Am J Med Genet. 2000 Oct 9;96(5):665-70
references.pmid: 11054775
references.citation: Am J Med Genet. 1999 Aug 20;88(4):391-7
references.pmid: 10402507
references.citation: N Engl J Med. 1992 Sep 17;327(12):829-33
references.pmid: 1508241
references.citation: Twin Res Hum Genet. 2006 Feb;9(1):64-72
references.pmid: 16611469
references.citation: J Behav Health Serv Res. 2005 Oct-Dec;32(4):381-92
references.pmid: 16215448
references.citation: Nicotine Tob Res. 2003 Apr;5(2):245-54
references.pmid: 12745498
references.citation: JAMA. 1994 Feb 23;271(8):589-94
references.pmid: 8301790
references.citation: BMC Genet. 2007 Apr 03;8:10
references.pmid: 17407593
references.citation: Tob Control. 2006 Jun;15(3):152-9
references.pmid: 16728744